Orgenesis Inc. (ORGS) Social Stream



Orgenesis Inc. (ORGS): $1.20

0.00 (0.00%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

F

ORGENESIS INC (ORGS) Price Targets From Analysts

Use the tables below to see what analysts covering ORGENESIS INC think about its future price and what recommendations they have for investors and traders.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2022-04-14 1 $9 $9 $9 $0.382 2256.02%
2023-03-22 1 $6 $6 $6 $0.382 1470.68%

Price Target Last Issued March 22, 2023

The Trend in the Analyst Price Target


ORGS's average price target has moved down $3 over the prior 23 months.

500 - Internal server error

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2023-03-22 1 6 6 6 1.34 347.76%

ORGS Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1 1 0 0 0 0 1

The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for ORGS as an investment opportunity.

  • To contextualize these metrics, consider that out of all US stocks, ORGENESIS INC's number of analysts covering the stock is higher than just about none of of them.
  • ORGENESIS INC's variance in analysts' estimates is lower than nearly 100% of all US stocks.
  • In the context of Healthcare stocks, ORGENESIS INC's upside potential (average analyst target price relative to current price) is greater than 190.43% of them.
  • ORGENESIS INC's average analyst price target is higher than 24.09% of Healthcare stocks.

Stocks similar to ORGENESIS INC in the Pharmaceutical Products industry regarding analyst recommendations and price targets are EVOK, NBY, and SNOA.

Make investment decisions regarding ORGS using the data that counts. Try POWR Ratings for free.


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!